December 17, 2021

From ASPHALION, we would like to inform you of the opening of the call:

  • HORIZON-HLTH-2022-DISEASE-06-02-two-stage: “Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs”


This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”.

Immunotherapy is defined as a treatment able to stimulate or restore the ability of the immune (defence) system to fight infection, disease or disorder. It has proved to be a valuable medical treatment notably when preventive interventions are not available. Passive and active immunotherapies (such as antibody-based, RNA-based and cell-based therapies, respectively) are covered by this topic, which is aiming at the pre-clinical to first-in human development of next generation immunotherapies for unmet needs.

ASPHALION, as SME company, is actively involved in more than 15 EU granted projects as regulatory expert partners.

Whether you are planning to apply and you would like to add a regulatory partner to the project, or if you are interested in knowing more about ASPHALION and our European granted projects expertise, do not hesitate to contact us at: horizon@asphalion.com




Search News & Events

  • Filter by category


Related news and events


‘RBDCOV Talks’ brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting